These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25600045)

  • 1. [Extended options of anticoagulant treatment in thromboembolism].
    Karetová D; Bultas J
    Vnitr Lek; 2014 Nov; 60(11):977-84. PubMed ID: 25600045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
    Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
    Cohen A; Drost P; Marchant N; Mitchell S; Orme M; Rublee D; Simon TA; Sutton A
    Clin Appl Thromb Hemost; 2012 Nov; 18(6):611-27. PubMed ID: 22387582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New oral anticoagulant agents: the quandary of anticoagulation in the elderly].
    Páramo JA
    Med Clin (Barc); 2013 Oct; 141(8):346-8. PubMed ID: 23831406
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
    Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
    Kasmeridis C; Lip GY; Apostolakis S
    Hosp Pract (1995); 2013 Feb; 41(1):61-70. PubMed ID: 23466968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New oral anticoagulants are as safe in elderly patients as conventional drugs].
    Steurer J
    Praxis (Bern 1994); 2014 Aug; 103(17):1032. PubMed ID: 25146949
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
    Gorzelak-Pabiś P; Duraj I; Szlagowska L; Ciastkowska A; Broncel M
    Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Differential therapy with the new anticoagulants, 5].
    Stiefelhagen P
    MMW Fortschr Med; 2013 May; 155(9):20. PubMed ID: 23951642
    [No Abstract]   [Full Text] [Related]  

  • 16. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
    Douketis J; Bell AD; Eikelboom J; Liew A
    Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches to reversing oral anticoagulant therapy. Introduction.
    Nutescu EA
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S1-2. PubMed ID: 23640527
    [No Abstract]   [Full Text] [Related]  

  • 18. {blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
    Drug Ther Bull; 2014 Jan; 52(1):6-9. PubMed ID: 24401533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
    Loke YK; Kwok CS
    J Clin Pharm Ther; 2011 Feb; 36(1):111-24. PubMed ID: 21198726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
    Fenger-Eriksen C; Münster AM; Grove EL
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):651-9. PubMed ID: 24716468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.